<table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">CRISP genes</th>
<th align="left" colspan="1" rowspan="1">Research implicating gene expression in lipid dysregulation</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Alg5</em></td>
<td align="left" colspan="1" rowspan="1">N/A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Apoc1</em></td>
<td align="left" colspan="1" rowspan="1">Fuior, E. V. &amp; Gafencu, A. V. Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond. <em>IJMS</em>
<strong>20</strong>, 5939 (2019)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Apoc3</em></td>
<td align="left" colspan="1" rowspan="1">Paiva, A. A., Raposo, H. F., Wanschel, A. C. B. A., Nardelli, T. R. &amp; Oliveira, H. C. F. Apolipoprotein CIII Overexpression‐Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death. <em>Oxidative Medicine and Cellular Longevity</em>
<strong>2017</strong>, 1838679 (2017)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Apoe</em></td>
<td align="left" colspan="1" rowspan="1">Lu, W. <em>et al.</em> ApoE deficiency promotes non-alcoholic fatty liver disease in mice via impeding AMPK/mTOR mediated autophagy. <em>Life Sciences</em>
<strong>252</strong>, 117601 (2020)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Cyp2e1</em></td>
<td align="left" colspan="1" rowspan="1">Harjumäki, R., Pridgeon, C. S. &amp; Ingelman-Sundberg, M. CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. <em>IJMS</em>
<strong>22</strong>, 8221 (2021)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Cyp3a41b</em></td>
<td align="left" colspan="1" rowspan="1">Woolsey, S. J., Mansell, S. E., Kim, R. B., Tirona, R. G. &amp; Beaton, M. D. CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. <em>Drug Metab Dispos</em>
<strong>43</strong>, 1484–1490 (2015)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Fasn</em></td>
<td align="left" colspan="1" rowspan="1">O’Farrell, M. <em>et al.</em> FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. <em>Sci Rep</em>
<strong>12</strong>, 15661 (2022)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Gamt</em></td>
<td align="left" colspan="1" rowspan="1">Marinello, P. C. <em>et al.</em> Creatine supplementation protects against diet-induced non-alcoholic fatty liver but exacerbates alcoholic fatty liver. <em>Life Sciences</em>
<strong>310</strong>, 121064 (2022)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Scd1</em></td>
<td align="left" colspan="1" rowspan="1">Sun, Q. <em>et al.</em> SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors. <em>Biomedicine &amp; Pharmacotherapy</em>
<strong>170</strong>, 115586 (2024)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"><em>Star</em></td>
<td align="left" colspan="1" rowspan="1">Qiu, Y. <em>et al.</em> Steroidogenic acute regulatory protein (StAR) overexpression attenuates HFD-induced hepatic steatosis and insulin resistance. <em>Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease</em>
<strong>1863</strong>, 978–990 (2017)</td>
</tr>
</tbody>
</table>